Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €3.81 EUR
Change Today +0.015 / 0.40%
Volume 0.0
As of 10:09 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

300 The American Road

Morris Plains, NJ 07950

United States

Phone: 973-605-8200

Fax: 973-605-8282

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other serious diseases. Clinical Programs Epratuzumab The company’s therapeutic product candidate, epratuzumab, is a humanized antibody, which targets CD22, an antigen found on the surface of B-lymphocytes, a type of white blood cell critical to proper immune system function. Elevated expression of CD22 and other B-cell receptor - associated proteins on B-lymphocytes has been associated with systemic lupus erythematosus (SLE), chronic autoimmune diseases and also with certain cancers. The company has retained the rights to epratuzumab in oncology and continues to develop this product candidate in oncology indications, namely in non-Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia, in cooperation with study groups in the U.S. and Europe. The company’s partner, UCB, S.A. (UCB), is evaluating epratuzumab in two Phase 3 clinical trials in SLE. Yttrium-90-Labeled Clivatuzumab Tetraxetan 90Y-clivatuzumab tetraxetan is the company’s therapeutic product candidate for patients with pancreatic cancer. This product candidate utilizes radioimmunotherapy, which combines the targeting power of monoclonal antibodies with the cell-damaging ability of localized radiation. Antibody-Drug Conjugates (ADCs) The company has three product candidates from its proprietary ADC program that are in clinical development, two of which focus on the treatment of patients with metastatic solid tumors. IMMU-130 is an anti-CEACAM5-SN-38 ADC in development for the treatment of metastatic colorectal cancer. IMMU-132 IMMU-132 is an ADC that contains SN-38, the active metabolite of irinotecan, approved by many Health Authorities, including the U.S. Food and Drug Administration (FDA) as a chemotherapeutic for patients with cancer. IMMU-132 was created at Immunomedics by conjugating SN-38 to hRS7, an anti-TROP-2 antibody. TROP-2 is a cell-surface receptor that while over-expressed by many human tumors, including cancers of the breast, colon and lung, has limited expression in normal human tissues. hRS7 internalizes into cancer cells following binding to TROP-2, making it a suitable candidate for the delivery of cytotoxic drugs. IMMU-132 has received orphan drug designation from the FDA for the treatment of patients with small cell lung cancer (SCLC) or pancreatic cancer. In addition to SCLC and pancreatic cancer, IMMU-132 is in Phase 2 clinical development focusing on select types of solid cancers, including triple-negative breast cancer and colorectal cancer. IMMU-130 The company’s second investigational solid-tumor ADC involves its labetuzumab antibody, anti-CEACAM5, conjugated to SN-38. The agent is being studied in patients with metastatic colorectal cancer who had received at least one prior irinotecan-containing regimen and had an elevated blood titer of carcinoembryonic antigen. Early-Stage Programs The company has additional potential products for the treatment of cancer and autoimmune diseases, including veltuzumab, its anti-CD20 antibody, and milatuzumab, its anti-CD74 antibody. Veltuzumab is being evaluated in an NCI-funded Phase 2 study in combination with 90Y-epratuzumab tetraxetan in patients with aggressive NHL. Milatuzumab is being developed for the treatment of graft-versus-host disease and has also received a Department of Defense grant for a clinical study in patients with lupus. In addition, milatuzumab conjugated with doxorubicin is in a Phase 1 dose-escalation trial in patients with relapsed NHL or chronic lymphocytic leukemia (CLL). Other programs include IMMU-114, a humanized anti-HLA-DR antibody being investigated as a monotherapy for NHL and CLL. Veltuzumab Veltuzumab is a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes under development for the treatment of NHL and autoimmune diseases. In autoimmune diseases, the company is studying the subcutaneous formulation of veltuzumab in patients with immune thrombocytopenia (ITP). Milatuzumab Milatuzumab is a humanized monoclonal antib

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM3:GR €3.81 EUR +0.015

IM3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IM3.
View Industry Companies
 

Industry Analysis

IM3

Industry Average

Valuation IM3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 86.3x
Price/Book 23.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 81.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOMEDICS INC, please visit www.immunomedics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.